PepGen Reports Q3 GAAP EPS of -$0.28, Slightly Missing Estimates
PepGen (PEPG) reported third-quarter GAAP earnings per share of -$0.28, missing analyst expectations by $0.01. Despite the slight earnings miss, the company maintains a stable liquidity position with $104.8 million in cash, cash equivalents, and marketable securities as of September 30, 2026. The biotechnology firm stated that its current capital reserves are expected to be sufficient to fund operations through 2028. This financial runway provides stability as the company continues clinical development, particularly following recent positive data regarding its PGN-EDODM1 mid-stage trial for muscle disorder therapies.
Tickers: $PEPG